贝达喹啉、氯法齐明和德拉马尼对常见致病性非结核分枝杆菌体外抑菌活性及耐药机制的研究进展

In vitro activities and drug resistance mechanisms of bedaquiline,clofazimine and delamanid against common pathogenic nontuberculous mycobacteria

近年来,非结核分枝杆菌(non-tuberculous mycobacteria,NTM)引起的感染呈逐渐上升趋势,严重威胁人类健康。NTM致病的菌种繁多,不同菌种NTM对药品的敏感性各异,使其治疗存在较大困难。因此,寻找NTM病治疗效果较佳的药品非常有必要。NTM种属分布常具有地域特点,在多数地区鸟-胞内分枝杆菌复合群、脓肿分枝杆菌和堪萨斯分枝杆菌为较常见的致病菌种。贝达喹啉(bedaquiline,Bdq)、氯法齐明(clofazimine,Cfz)及德拉马尼(delamanid,Dlm)因对治疗NTM病体现出了良好的治疗潜力而受到广泛关注。为了提高对抗NTM药品敏感性及耐药机制的认识,作者就Bdq、Cfz和Dlm对以上常见致病性NTM的体外抑菌活性及耐药相关机制进行综述。

Recently,the infection of non-tuberculous mycobacteria(NTM)has increased rapidly and threatened human health.NTM differentiate into many species.Species diversity makes treatment of NTM extremely difficult.Thus,it is very important to find new and effective drugs.Bedaquiline,clofazimine and delamanid showed effectiveness in treating NTM.In order to improve the understanding of drug susceptibility and drug resistance mechanism of NTM,in vitro activities and drug resistance mechanisms of bedaquiline,clofazimine and delamanid against common pathogenic are described.